Aplastic Anemia

Table of Contents

  1. What is Aplastic Anemia?
  2. Pathophysiology: Immune-Mediated Marrow Failure
  3. Causes and Risk Factors
  4. Severity Classification
  5. Clinical Presentation and Diagnosis
  6. Bone Marrow Biopsy Findings
  7. Differential Diagnosis
  8. Treatment: Allogeneic Stem Cell Transplantation
  9. Treatment: Immunosuppressive Therapy (IST)
  10. Prognosis and Clonal Evolution
  11. Research Papers
  12. Connections
  13. Featured Videos

What is Aplastic Anemia?

Aplastic anemia is a life-threatening bone marrow failure syndrome in which the bone marrow stops producing enough blood cells. Unlike the more familiar iron-deficiency or B12-deficiency anemias, aplastic anemia is not a nutritional problem — it is a failure of the bone marrow's ability to generate all three blood cell lines simultaneously. This triple deficiency is called pancytopenia: anemia (too few red blood cells), neutropenia (too few neutrophils/white blood cells), and thrombocytopenia (too few platelets).

The underlying cause is destruction or severe suppression of hematopoietic stem cells (HSCs) — the master cells in the bone marrow that give rise to every blood cell type. Without a functional HSC pool, the marrow cannot sustain normal blood production. On biopsy, the marrow is hypocellular: its normal hematopoietic tissue has been replaced by fat cells, leaving a largely empty marrow cavity.

Aplastic anemia is rare but not vanishingly so. Incidence in Western countries is approximately 2 cases per 100,000 people per year, while rates in Asia (Japan, Thailand, China) are 2–3 times higher — a difference attributed to genetic background and possibly environmental exposures. The age distribution is bimodal, with peaks at 15–25 years and again after age 60. The reason for the younger peak is not fully understood but may relate to the timing of immune dysregulation.

Aplastic anemia can be acquired (the vast majority of cases) or inherited. The most important inherited forms are Fanconi anemia — caused by DNA repair defects and associated with short stature, café-au-lait spots, and radial bone abnormalities — and dyskeratosis congenita, driven by telomere shortening and characterized by nail dystrophy, oral leukoplakia, and abnormal skin pigmentation. Inherited cases typically present earlier in life and require different management considerations including heightened cancer surveillance.

Back to Table of Contents

Pathophysiology: Immune-Mediated Marrow Failure

In approximately 80% of acquired aplastic anemia cases, the marrow failure is driven by an autoimmune attack. The critical effectors are oligoclonal CD8+ cytotoxic T cells — a small, expanded population of autoreactive T cells that specifically target hematopoietic stem cells. These abnormal T cells are found in the marrow and peripheral blood of patients, and their numbers correlate with disease severity.

The immune attack proceeds through multiple mechanisms. Activated T cells release interferon-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α), cytokines that directly suppress hematopoiesis and trigger apoptosis (programmed cell death) in HSCs. The Fas/FasL pathway is a key mediator: IFN-γ upregulates Fas expression on HSCs, making them vulnerable to destruction by FasL-bearing T cells. The result is progressive depletion of the HSC pool, ultimately leading to marrow failure.

Several lines of evidence confirm this immune-mediated mechanism. First, the majority of patients respond to immunosuppressive therapy, which would not work if the marrow simply lacked stem cells. Second, there are clear HLA associations — certain HLA alleles (particularly HLA-DR2/DRB1*15:01) are overrepresented in aplastic anemia patients, pointing to an antigen-driven T-cell response. Third, abnormal T-cell repertoire clonality can be directly demonstrated in patients' blood and marrow.

A crucial overlapping finding is the presence of paroxysmal nocturnal hemoglobinuria (PNH) clones in approximately 50% of aplastic anemia patients at diagnosis. PNH clones are HSCs that have acquired a mutation in the PIG-A gene, which encodes an enzyme needed to attach GPI-anchor proteins to the cell surface. GPI-anchor proteins include CD55 and CD59, which normally protect cells from complement-mediated destruction. In the context of aplastic anemia, PNH clones appear to survive the immune attack preferentially — possibly because the absence of certain GPI-anchored proteins makes them less recognizable to autoreactive T cells. The coexistence of PNH clones and aplastic anemia is not coincidental; it reflects shared pathophysiology and has important clinical implications for thrombosis risk.

Back to Table of Contents

Causes and Risk Factors

Despite thorough investigation, most cases of aplastic anemia are classified as idiopathic — no triggering cause is identified. However, a number of established causes and risk factors are recognized.

Medications are an important and preventable cause. The classic culprit is chloramphenicol, an antibiotic now rarely used in developed countries precisely because of this risk. Other implicated drugs include gold salts (used historically in rheumatoid arthritis), carbamazepine (an anticonvulsant), NSAIDs, sulfonamide antibiotics, and propylthiouracil (used for hyperthyroidism). Drug-induced aplastic anemia is often an idiosyncratic reaction — it does not depend on dose and cannot be predicted. Suspicion should be raised when aplastic anemia develops within weeks to months of starting a new medication.

Viral infections are a significant trigger. Several viruses have been implicated: Epstein-Barr virus (EBV), parvovirus B19 (which has particular tropism for erythroid progenitors), and — most notably — hepatitis-associated aplastic anemia. This syndrome, sometimes called seronegative hepatitis-associated aplastic anemia, follows an acute hepatitis illness that tests negative for all known hepatitis viruses (A, B, C, E). The hepatitis typically precedes marrow failure by 2–3 months and is particularly severe; the aplastic anemia that follows is often very severe and requires prompt treatment. The causative virus remains unidentified.

Toxin exposures include benzene — a known bone marrow toxin found in industrial solvents, gasoline, and cigarette smoke — and ionizing radiation in sufficient doses. Agricultural pesticide exposure has been associated with aplastic anemia in some epidemiological studies. Pregnancy-associated aplastic anemia is rare but recognized; in some cases it remits after delivery.

Inherited bone marrow failure syndromes require specific consideration. Fanconi anemia (FA) is the most common inherited form, caused by mutations in FA pathway genes involved in DNA interstrand crosslink repair. Clinically, FA presents with short stature, café-au-lait spots, radial ray abnormalities (absent or hypoplastic thumbs/radii), and other congenital malformations. The diagnosis is confirmed by a chromosome fragility test using diepoxybutane (DEB) or mitomycin C, which reveals excess chromosomal breaks in FA cells. Dyskeratosis congenita results from mutations in telomere maintenance genes (TERT, TERC, DKC1, and others), causing accelerated telomere shortening. The classic triad is nail dystrophy, oral leukoplakia, and reticular skin pigmentation. Telomere length testing of leukocyte subsets is diagnostic.

Back to Table of Contents

Severity Classification

Aplastic anemia is classified by severity because severity directly governs treatment urgency and choice. The internationally accepted criteria, first established by Camitta and refined over subsequent decades, divide disease into three tiers.

Non-severe (moderate) aplastic anemia is defined by cytopenias and a hypocellular marrow that do not meet the criteria for severe disease. Patients may be transfusion-dependent but are not at immediate risk of life-threatening infection or hemorrhage. Watchful waiting or less intensive therapy may be appropriate in some cases.

Severe aplastic anemia (SAA) requires meeting at least 2 of 3 peripheral blood criteria:

These cutoffs reflect the threshold at which the risk of life-threatening infection and spontaneous bleeding becomes clinically significant. SAA demands prompt treatment — delay worsens outcomes due to complications of prolonged pancytopenia (fungal infections, intracranial hemorrhage).

Very severe aplastic anemia (vSAA) meets all SAA criteria but with an ANC <200/μL — a level at which the body is essentially defenseless against bacterial and fungal pathogens. vSAA carries the highest short-term mortality without treatment and requires the most urgent intervention, typically stem cell transplantation if a matched donor is available.

Severity classification is not a one-time assessment. Patients initially classified as non-severe can evolve to severe disease over weeks to months, and should be monitored closely with regular complete blood counts.

Back to Table of Contents

Clinical Presentation and Diagnosis

The symptoms of aplastic anemia reflect the three cell-line deficiencies of pancytopenia and typically develop gradually over weeks to months, though in severe cases the onset can be abrupt.

Anemia symptoms dominate early: progressive fatigue, exertional dyspnea, pallor of the skin, nail beds, and conjunctivae, palpitations, and reduced exercise tolerance. Because the anemia develops slowly in most cases, patients often adapt remarkably well to low hemoglobin levels before seeking medical attention.

Thrombocytopenia symptoms manifest as easy bruising, petechiae (tiny pinpoint hemorrhages in the skin), purpura, prolonged bleeding from minor cuts, gingival bleeding, and epistaxis. In severe thrombocytopenia (platelets <10,000/μL), spontaneous intracranial or gastrointestinal hemorrhage becomes a risk.

Neutropenia symptoms are infections. Patients are vulnerable to bacterial infections (gram-negative organisms, Staphylococcus aureus), fungal infections (Candida, Aspergillus), and viral reactivations. Neutropenic fever — defined as a single oral temperature above 38.3°C or a sustained temperature above 38.0°C in a patient with ANC <500/μL — is a medical emergency requiring immediate hospitalization and broad-spectrum antibiotics.

Importantly, aplastic anemia does not cause splenomegaly or lymphadenopathy. The presence of an enlarged spleen or lymph nodes should prompt reconsideration of the diagnosis and workup for leukemia, lymphoma, or other infiltrative disorders.

Diagnostic workup begins with a complete blood count (CBC) showing pancytopenia, and a peripheral blood smear showing reduced numbers of all cell lines without morphological abnormalities (no blasts, no hypersegmented neutrophils). Reticulocyte count is low, confirming impaired marrow production rather than peripheral destruction. A bone marrow biopsy is essential — it confirms hypocellularity and excludes alternative diagnoses. Additional tests include flow cytometry for PNH clones, cytogenetics, telomere length testing (if inherited syndrome suspected), and viral serologies.

Back to Table of Contents

Bone Marrow Biopsy Findings

The bone marrow biopsy is the cornerstone of aplastic anemia diagnosis. In aplastic anemia, the biopsy reveals a dramatically hypocellular marrow — typically cellularity below 25%, often below 10%, compared to the age-expected normal (roughly 100 minus age as a percent). What was once a densely packed space teeming with developing blood cell precursors is largely replaced by fat cells and empty space.

Microscopically, the residual cellular elements are predominantly lymphocytes and plasma cells — the inflammatory infiltrate that reflects the underlying immune attack. Hematopoietic precursors (erythroid progenitors, myeloid precursors, megakaryocytes) are markedly reduced or absent. The marrow architecture is preserved, meaning the basic scaffolding is intact even as the functional cells have disappeared.

Several findings on biopsy are conspicuous by their absence — and their absence matters diagnostically. There is no dysplasia (abnormal cell morphology), which helps distinguish aplastic anemia from myelodysplastic syndrome (MDS). There are no excess blasts, which distinguishes aplastic anemia from acute leukemia. There is no reticulin fibrosis, which distinguishes it from myelofibrosis. The marrow is empty, not replaced by abnormal cells.

Flow cytometry of peripheral blood or marrow aspirate is performed to detect PNH clones — populations of granulocytes and red blood cells lacking GPI-anchor proteins (CD55, CD59). PNH clone detection has become a standard part of the aplastic anemia workup because it confirms the immune-mediated pathophysiology and has direct management implications (anticoagulation decisions, monitoring for hemolysis).

Cytogenetics (conventional karyotype and/or FISH) are typically normal in aplastic anemia. The presence of clonal cytogenetic abnormalities — particularly del(5q), del(7q), monosomy 7, trisomy 8 — raises the possibility of a hypoplastic MDS variant rather than true aplastic anemia. This distinction matters because MDS and aplastic anemia have different natural histories and, in some cases, different optimal treatments. Increasingly, somatic mutation profiling (next-generation sequencing for mutations in DNMT3A, ASXL1, RUNX1, and other myeloid genes) is being used to characterize clonal architecture at diagnosis.

Back to Table of Contents

Differential Diagnosis

Establishing the correct diagnosis before treatment is critical, because the diseases that mimic aplastic anemia often require entirely different management approaches. The key conditions to distinguish are:

Hypoplastic myelodysplastic syndrome (MDS) can be the most challenging differential. Both present with pancytopenia and a hypocellular marrow. The distinguishing features of MDS are dysplastic morphological changes on marrow biopsy (abnormal nuclear shapes, ringed sideroblasts), clonal cytogenetic abnormalities, and excess blasts (>5% in the marrow). Treatment is different: MDS may require hypomethylating agents or transplant based on risk score, and immunosuppressive therapy is less effective.

Acute leukemia with hypoplastic presentation is rare but can superficially resemble aplastic anemia. The presence of circulating or marrow blasts, specific cytogenetic lesions, and often a more acute clinical course distinguish leukemia. Flow cytometry is essential.

Large granular lymphocyte (LGL) leukemia is a clonal proliferation of cytotoxic T cells (or NK cells) that frequently causes neutropenia, and sometimes broader cytopenias. The diagnosis requires identifying a specific T-cell clone (by flow cytometry and/or TCR gene rearrangement studies) and, in many cases, a STAT3 mutation. LGL leukemia responds to cyclosporine or methotrexate — the overlap with aplastic anemia treatment is not coincidental, as the pathophysiology involves aberrant cytotoxic lymphocytes in both.

Paroxysmal nocturnal hemoglobinuria (PNH) as a primary disorder (as opposed to PNH clones within aplastic anemia) presents with intravascular hemolysis, thrombosis, and cytopenias. Flow cytometry showing a large PNH clone (>50% of granulocytes), along with hemolysis markers (elevated LDH, reduced haptoglobin), points to primary PNH. Management with the complement inhibitor eculizumab is specifically indicated for large PNH clones causing hemolysis or thrombosis.

Nutritional deficiencies — particularly severe vitamin B12 or folate deficiency — cause pancytopenia but with a characteristically hypercellular marrow (megaloblastic anemia). Hypersegmented neutrophils on peripheral smear and the appropriate nutritional history are key clues. B12/folate levels should be checked in any patient presenting with pancytopenia.

Marrow infiltration by metastatic cancer, granulomatous disease (sarcoidosis, tuberculosis), or other processes can displace normal hematopoiesis. The biopsy will show the infiltrating cells, not just fat replacement.

Back to Table of Contents

Treatment: Allogeneic Stem Cell Transplantation

Allogeneic stem cell transplantation (alloSCT) is the only curative treatment for aplastic anemia and is the preferred treatment for young patients (age ≤40 years) with severe or very severe aplastic anemia who have a matched sibling donor (MSD). In this optimal setting, transplantation offers long-term cure rates of 80–90%.

The rationale is straightforward: because aplastic anemia results from an immune-mediated attack on the patient's own HSCs, replacing both the defective immune system and the depleted stem cell pool simultaneously with donor cells addresses the root cause. The conditioning regimen used before MSD-transplant in aplastic anemia — typically cyclophosphamide plus anti-thymocyte globulin (ATG) — is intentionally less intense than the myeloablative conditioning used for leukemia, because the goal is immunosuppression and graft facilitation, not killing leukemic cells.

The major complications are graft failure (the donor cells do not engraft, leaving the patient with ongoing marrow failure) and graft-versus-host disease (GvHD), in which donor immune cells attack the recipient's tissues. Acute GvHD typically affects the skin, gut, and liver; chronic GvHD can affect multiple organ systems and significantly impairs quality of life. The risk of GvHD is lower with matched sibling transplants than with unrelated donor transplants.

For patients without a matched sibling donor, matched unrelated donor (MUD) transplantation is increasingly used, particularly for younger patients and those who fail immunosuppressive therapy. Historically, outcomes with MUD transplants were substantially worse than MSD transplants. However, with improved high-resolution HLA matching, the use of fludarabine-based conditioning regimens (which provide better immunosuppression with less toxicity than older cyclophosphamide-based regimens), and advances in GvHD prophylaxis, cure rates with well-matched unrelated donors have improved to 70–85%. Haploidentical (half-matched) transplants using post-transplant cyclophosphamide are being studied as an option when fully matched donors are unavailable.

AlloSCT is also the treatment of choice for patients with refractory or relapsed disease after immunosuppressive therapy. The timing of transplant in these patients is important — prolonged pancytopenia before transplant increases the risk of infection-related complications. Age, performance status, comorbidities, and donor availability all factor into the transplant decision.

Back to Table of Contents

Treatment: Immunosuppressive Therapy (IST)

For patients not eligible for allogeneic stem cell transplantation — typically those older than 40 years, those lacking a suitable donor, or those with comorbidities that make transplant too risky — immunosuppressive therapy (IST) is the standard treatment. IST targets the aberrant T-cell response underlying the disease.

The backbone of IST is horse anti-thymocyte globulin (hATG, equine ATG), a polyclonal antibody preparation derived from horses immunized with human thymocytes. Administered intravenously over 4–5 days, hATG depletes activated T cells that are attacking the bone marrow. This is combined with cyclosporine A (CsA), a calcineurin inhibitor that blocks T-cell activation by inhibiting IL-2 production. CsA is continued for at least 12–24 months to sustain immune suppression and reduce the risk of relapse.

A landmark development came from a 2017 NEJM trial by Townsley et al., which demonstrated that adding eltrombopag — a thrombopoietin receptor agonist that stimulates platelet production and, importantly, also promotes HSC self-renewal — to hATG and CsA significantly improved outcomes. Complete response rates improved from approximately 40% to 60% with the triple combination, and overall hematopoietic response rates were higher. Eltrombopag is now standard as part of first-line IST for aplastic anemia.

An important nuance: rabbit ATG (rATG, thymoglobulin), which is commonly used in organ transplantation and for leukemia conditioning, is inferior to horse ATG for aplastic anemia. A randomized trial by Scheinberg et al. (2012) demonstrated this clearly — rATG produced significantly lower response rates. This distinction matters clinically because rATG is more widely available and may be substituted in error.

Response to IST is assessed at 3–6 months. Patients who do not respond adequately can receive a second course of IST (either a second course of hATG or alternative agents) or be referred for stem cell transplantation. Danazol, a synthetic androgen, may help maintain hematological responses and is sometimes used as maintenance therapy. Androgens (such as oxymetholone) have activity in aplastic anemia and are an option for elderly patients or those unsuitable for intensive therapy.

Supportive care is an essential and underappreciated component of management throughout treatment. Red blood cell and platelet transfusions support patients until their marrow recovers. G-CSF (granulocyte colony-stimulating factor) is given during and after IST to reduce the duration of neutropenia and the risk of infection. Prophylactic antifungal and antibacterial agents are standard during periods of severe neutropenia. Patients who require long-term transfusion support develop progressive iron overload, which requires treatment with iron chelators (deferoxamine or deferasirox) to prevent cardiac and hepatic toxicity.

Back to Table of Contents

Prognosis and Clonal Evolution

The prognosis of aplastic anemia has improved dramatically over the past four decades. With modern treatment — either allogeneic stem cell transplantation or triple IST (hATG + CsA + eltrombopag) — 5-year survival rates of 75–85% are achievable in experienced centers. Younger patients and those with a matched sibling donor who undergo early transplantation have the best outcomes. IST non-responders have substantially worse prognosis and should be evaluated promptly for alternative approaches.

Long-term survivors of IST face several important risks. Relapse occurs in approximately 30% of IST-treated patients, typically within the first few years after treatment. Most relapses respond to a second course of IST, but each relapse erodes the HSC pool further. Extended cyclosporine tapering (over 2 years rather than abruptly stopping) reduces relapse risk.

PNH clone evolution is a significant long-term concern. In approximately 30% of IST-treated patients, pre-existing small PNH clones expand over time into clinically significant populations. Large PNH clones carry risks of intravascular hemolysis, venous thrombosis (particularly in unusual sites like hepatic veins causing Budd-Chiari syndrome or cerebral veins), and arterial thrombosis. Patients with aplastic anemia should be monitored periodically with flow cytometry for PNH clone size. Prophylactic anticoagulation is considered for patients with large clones, and the complement inhibitor eculizumab (or newer agents ravulizumab and iptacopan) is the treatment of choice when hemolysis or thrombosis occurs.

The most feared long-term complication is clonal evolution to myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML), occurring in 10–15% of IST-treated patients over 10–15 years. This reflects the inherent genomic instability of the aplastic anemia clone and the selective pressures exerted by the immune microenvironment. Recent research (Yoshizato et al., 2015) showed that somatic mutations in myeloid driver genes — particularly DNMT3A, ASXL1, and RUNX1 — detected at the time of aplastic anemia diagnosis predict a higher risk of subsequent clonal evolution. This finding is driving interest in baseline somatic mutation profiling to risk-stratify patients and inform monitoring intensity.

AlloSCT recipients are not free of long-term complications. Chronic graft-versus-host disease affects a significant proportion of transplant survivors and can cause systemic fibrosis, sicca symptoms, lung disease, and reduced quality of life requiring ongoing immunosuppressive therapy for years. However, for transplant recipients who achieve durable engraftment without significant GvHD, the risk of MDS/AML and PNH expansion is essentially eliminated — the defective clone is replaced by donor hematopoiesis.

Back to Table of Contents

Research Papers

The following PubMed links point to pivotal peer-reviewed studies on aplastic anemia, covering pathophysiology, clinical trials, immunosuppressive therapy, and stem cell transplantation.

Back to Table of Contents

Connections

Back to Table of Contents